Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.65M | -130.21M | -132.07M | -37.00M | -58.68M |
| Total Depreciation and Amortization | 564.00K | 692.00K | 807.00K | 892.00K | 932.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.67M | 99.21M | 100.26M | -6.98M | -3.13M |
| Change in Net Operating Assets | 23.43M | 17.99M | 10.92M | 25.19M | -3.58M |
| Cash from Operations | -9.99M | -12.32M | -20.08M | -17.90M | -64.46M |
| Capital Expenditure | -64.00K | -29.00K | -121.00K | -562.00K | -646.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -61.70M | -67.45M | -69.65M | 27.07M | 56.89M |
| Cash from Investing | -61.76M | -67.48M | -69.77M | 26.50M | 56.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 80.03M | 80.03M | 80.03M | 907.00K | 890.00K |
| Repurchase of Common Stock | -627.00K | -629.00K | -409.00K | -76.00K | -168.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.09M | -5.09M | -5.09M | -826.00K | -826.00K |
| Cash from Financing | 74.32M | 74.32M | 74.54M | 5.00K | -104.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.57M | -5.48M | -15.31M | 8.61M | -8.32M |